Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer

JOURNAL ARTICLE published 1 October 2017 in Cancer Discovery

Research funded by Susan G. Komen (PG12220321) | CPRIT (RR140033) | CPRIT (R01 CA095614) | CPRIT (CCR16380599) | NCI NIH (U10CA180821,U10CA180882,U10CA077440,U10CA180833,U10CA180858) | Siteman Cancer Center (P30 CA91842) | NCI NIH (3P30 CA091842-12S2) | CPRIT (RP120092) | NCI (P30CA125123)

Authors: Svasti Haricharan | Nindo Punturi | Purba Singh | Kimberly R. Holloway | Meenakshi Anurag | Jacob Schmelz | Cheryl Schmidt | Jonathan T. Lei | Vera Suman | Kelly Hunt | John A. Olson | Jeremy Hoog | Shunqiang Li | Shixia Huang | Dean P. Edwards | Shyam M. Kavuri | Matthew N. Bainbridge | Cynthia X. Ma | Matthew J. Ellis